Apremilast as an Oral Immunomodulator: Pharmacological Insights, Clinical Applications, and Emerging Perspectives

Shital Choudhary
Pharmacy Department, Alard School of Pharmacy, Pune, India

***Abstract*— Apremilast is an orally active, selective phosphodiesterase-4 (PDE-4) inhibitor developed for the treatment of chronic inflammatory disorders. By inhibiting PDE-4, Apremilast increases intracellular cyclic adenosine monophosphate levels, which in turn modulates the production of inflammatory mediators. The drug reduces the expression of pro-inflammatory cytokines such as tumour necrosis factor-α, interleukin-17, and interleukin-23 while enhancing anti-inflammatory cytokines. Apremilast has been approved for the management of moderate to severe plaque psoriasis and active psoriatic arthritis and has shown promising outcomes in terms of efficacy, safety, and patient compliance. Compared with biologic therapies, Apremilast offers the advantage of oral administration and a favourable tolerability profile. This review summarizes the chemistry, mechanism of action, pharmacokinetics, pharmacological effects, clinical efficacy, safety aspects, and recent advances related to Apremilast therapy, highlighting its current role and future potential in inflammatory disease management.**

***Index Terms*— Apremilast, phosphodiesterase-4 inhibitor, psoriasis, psoriatic arthritis, immunomodulator.**

I. INTRODUCTION

Inflammatory and autoimmune disorders such as psoriasis and psoriatic arthritis significantly affect physical health, psychological well-being, and quality of life. Conventional systemic therapies are often associated with long-term toxicity and require continuous monitoring, while biologic agents, though effective, involve high costs and parenteral administration. The need for safe and effective oral alternatives has led to the development of targeted small-molecule therapies.

Apremilast is a novel immunomodulatory agent that selectively inhibits phosphodiesterase-4, a key enzyme involved in the regulation of inflammatory responses. Since its approval, Apremilast has gained attention due to its unique mechanism of action, ease of administration, and acceptable safety profile. This review aims to provide a comprehensive overview of Apremilast, focusing on its pharmacological properties, therapeutic applications, clinical evidence, and recent developments.

II. CHEMICAL AND PHYSICOCHEMICAL PROPERTIES

Apremilast is a synthetic small-molecule compound belonging to the class of benzamide derivatives.



Table: Physicochemical Properties of Apremilast

Parameter	Description
Molecular Formula	$C_{22}H_{24}N_2O_3$
Molecular Weight	372.44 g/mol
Appearance	White to off-white crystalline powder
Solubility	Slightly soluble in water; freely soluble in organic solvents
Log P	Approximately 1.8

III. MECHANISM OF ACTION

Phosphodiesterase-4 is responsible for the degradation of cyclic adenosine monophosphate in immune cells. Inhibition of PDE-4 by apremilast leads to increased intracellular cAMP levels, resulting in suppression of pro-inflammatory cytokine production and enhancement of anti-inflammatory mediators. This regulatory effect on cytokine balance reduces inflammation and immune activation associated with psoriasis and psoriatic arthritis.

IV. PHARMACOKINETICS

Apremilast is rapidly absorbed after oral administration, with peak plasma concentration achieved within approximately 2–3 hours. The drug exhibits moderate bioavailability and is extensively metabolized in the liver, primarily by the CYP3A4 enzyme system. The elimination half-life ranges between 6 and 9 hours, and excretion occurs through both renal and fecal pathways.

V. PHARMACOLOGICAL ACTIONS

- Anti-inflammatory activity
- Immunomodulatory effect
- Reduction of keratinocyte hyperproliferation

VI. THERAPEUTIC USES

- Moderate to severe plaque psoriasis
- Active psoriatic arthritis
- Investigational use in Behçet's disease and other inflammatory conditions

VII. CLINICAL EFFICACY

Clinical trials such as ESTEEM and PALACE demonstrated significant improvement in disease severity scores and functional outcomes in patients treated with apremilast compared to placebo. Improvements were also observed in patient-reported quality-of-life parameters.

VIII. ADVERSE EFFECTS AND SAFETY PROFILE

The most commonly reported adverse effects include nausea, diarrhoea, headache, and weight loss. Most adverse reactions are mild to moderate and occur during the initial phase of treatment. Rare neuropsychiatric effects such as mood changes have been reported, necessitating patient monitoring.

IX. DRUG INTERACTIONS

Strong CYP3A4 inducers may reduce plasma concentrations of apremilast, potentially decreasing therapeutic efficacy. Caution is advised when co-administered with such agents.

X. RECENT ADVANCES AND FUTURE SCOPE

Ongoing research is focused on evaluating apremilast in combination therapies, exploring new therapeutic indications, and developing improved formulations to enhance patient outcomes.

XI. CONCLUSION

Apremilast represents an effective oral therapeutic option for chronic inflammatory disorders with a favourable safety and tolerability profile. Its targeted mechanism of action and convenience of administration make it a valuable alternative to conventional systemic and biologic therapies.

REFERENCES

[1] Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a novel PDE4 inhibitor, demonstrates anti-inflammatory activity in vitro and in vivo models of psoriasis. Br J Pharmacol. 2014;171(4):846-858.

[2] Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results of phase III ESTEEM trials. J Am Acad Dermatol. 2015;73(1):37-49.

[3] Mease PJ, Kavanaugh A, Coates LC, et al. Efficacy and safety of apremilast in patients with psoriatic arthritis: Results from the PALACE 1 trial. Ann Rheum Dis. 2015;74(7):1330-1338.

[4] Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Long-term safety and efficacy of apremilast in psoriatic arthritis. Arthritis Res Ther. 2019;21(1):1-12.

[5] Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast over 52 weeks in patients

with moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2018;32(12):2133-2141.
[6] Schafer PH, Truzzi F, Parton A, et al. Modulation of cytokine production by apremilast in immune cells. Int Immunopharmacol. 2016; 38:116-124.
[7] Dogra S, Mahajan R. Apremilast: A new oral option for psoriasis and psoriatic arthritis. Indian J Dermatol Venereol Leprol. 2016;82(3):256-262.
[8] Torres T, Puig L. Apremilast in the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2018;31(2): e12535.
[9] Keating GM. Apremilast: A review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459-472.
[10] Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-970.
[11] U.S. Food and Drug Administration. Otezla® (Apremilast) Prescribing Information. FDA; 2023.
[12] European Medicines Agency. Apremilast (Otezla®) EPAR – Product Information. EMA; 2023.
[13] Chimenti MS, Perricone R. Apremilast in the therapy of immune-mediated inflammatory diseases. Immunotherapy. 2017;9(4):341-355.
[14] Pincelli C, Schafer PH, French LE. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Exp Dermatol. 2018;27(5):482-487.
[15] Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab and apremilast: Comparison of clinical efficacy in psoriasis. J Am Acad Dermatol. 2016;74(6):1189-1197.
[16] Singh JA, Guyatt G, Ogdie A, et al. 2018 ACR/NPF guideline for psoriatic arthritis treatment. Arthritis Rheumatol. 2019;71(1):5-32.
[17] Reich K, Gooderham M, Green L, et al. Apremilast long-term safety up to 5 years. Br J Dermatol. 2020;182(6):1382-1391.
[18] Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of PDE-4 inhibition on immune regulation. Clin Exp Rheumatol. 2018;36(4):622-630.
[19] Bissonnette R, Luger T, Thaci D, et al. Apremilast in the treatment of Behçet's disease. N Engl J Med. 2019;381(20):1918-1928.
[20] Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016; 2:16082.
[21] Fiorentino D, Ho V, Lebwohl MG, et al. Systemic therapies for psoriasis: Mechanistic insights. Lancet. 2018;391(10136):2273-2284.
[22] Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for psoriasis. J Am Acad Dermatol. 2019;80(4):1029-1072.
[23] Mahil SK, Arkir Z, Richards G, et al. Predicting treatment response to apremilast. Br J Dermatol. 2020;182(4):863-873.
[24] van de Kerkhof PCM. Oral small molecules in psoriasis: Apremilast. Dermatol Clin. 2015;33(1):75-83.
[25] Schafer PH, Parton A, Capone L, et al. Apremilast pharmacokinetics and safety profile. Clin Pharmacokinet. 2016;55(4):411-422.